Medtronic Announces Intent To Spin Diabetes Business
(Photo Illustration by)
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.
Post spin-off, Medtronic (RemainCo) will continue to operate as a diversified MedTech innovator, concentrating on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies. Further, the company aims to accelerate growth through innovation in areas like pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation. Meanwhile, the New Diabetes Company (NewCo) will be offering a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring (CGM), and digital health solutions. The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) followed by a split-off. The transaction is expected to be tax-free to Medtronic shareholders for US federal income tax purposes. The separation will include the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities.
Medtronic Price Performance Spin-Off Details and Top 5 Shareholders
The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market. It is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in the dividend liability for Medtronic, enabling increased growth-accretive investment. Medtronic expects its dividend per share to remain unchanged pre- and post-transaction with no change to its dividend policy.
The spin-off is subject to customary regulatory approvals, board consent, and market conditions. Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of New Diabetes Company.
Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as financial advisors to Medtronic in its review of strategic alternatives for the New Diabetes Company.
Key Data
Deal Rationale
Medtronic, a global leader in MedTech, is planning to spin off its Diabetes business into a standalone entity, as part of a strategic move to sharpen its focus on higher-margin, faster-growing segments such as Cardiovascular, Neuroscience, and Medical-Surgical, which together account for over 90.0% of its total revenues.
The Diabetes segment, contributing approximately $2.5 billion in FY25 (about 8.0% of Medtronic's total $32.4 billion in revenue), has consistently underperformed over the past five years, with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR. Segment profitability has also lagged: while Medtronic's overall operating margin stands at ~15.9%, the diabetes unit has been a drag, reportedly generating operating losses in the low teens in its core U.S. market. In FY19, the segment posted a strong operating margin of 30.9% but steadily declined to 24.8–24.9% through FY21 and FY22, before dropping significantly to 15.8% in FY25.
Multiple headwinds contributed to this underperformance, including FDA regulatory setbacks, such as the 2021 warning letter and delayed approval of the MiniMed 780G insulin pump and Guardian 4 sensor, alongside intensifying competition from more agile players like Dexcom, Abbott, Tandem, and Insulet. These rivals outpaced Medtronic with faster innovation in continuous glucose monitoring (CGM) and closed loop insulin delivery systems. Furthermore, the rising adoption of GLP-1 receptor agonists (e.g., Ozempic, Mounjaro) is shifting treatment paradigms, particularly for Type 2 diabetes, reducing demand for insulin pumps.
Despite a recent rebound, with the diabetes segment growing ~10.7% YoY in FY25 and six consecutive quarters of double-digit growth, the improvement is seen as insufficient to offset the structural challenges and lower returns relative to the rest of Medtronic's portfolio. By spinning off the diabetes business, Medtronic aims to lift its gross margin by approximately 50 basis points, adjusted operating margins by approximately 100 basis points, and be immediately accretive to adjusted EPS.
As per management, following this separation, Medtronic is expected to increase focus on innovation-driven growth and category leadership for healthcare systems and physician customers. The company will have enhanced benefit from its scale and strategic commercial, manufacturing, and technology synergies.
On the other hand, this separation is expected to enable more focused investment into New Diabetes Company's pipeline, as well as manufacturing scale and automation, positioning the company for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time.
At the same time, it will create an independent, scaled leader in Diabetes, focused on accelerating innovation and differentiated as the only company to commercialize a complete ecosystem to address intensive insulin management.
The separation is also expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile.
Medtronic plc is a global healthcare technology leader that designs and manufactures medical devices and therapies to treat a wide range of chronic and acute health conditions. The company operates in over 150 countries and focuses on improving patient outcomes through innovation in areas such as AI, robotics, and data-driven care.
Medtronic's operations are structured into four major segments, each addressing a distinct area of healthcare technology. The Cardiovascular segment includes heart rhythm devices, heart valves, and vascular therapies for treating cardiac and circulatory conditions. The Neuroscience segment offers spinal implants, stroke treatment devices, and neuromodulation systems for managing neurological and musculoskeletal disorders. The Medical Surgical segment provides surgical tools, robotic-assisted systems, and patient monitoring technologies, while the Diabetes segment delivers insulin pumps, continuous glucose monitoring systems, and smart insulin pens to help manage diabetes effectively.
Cardiovascular: The Cardiovascular segment is dedicated to treating heart and vascular diseases through advanced medical technologies. It includes three subsegments: Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular. This segment offers pacemakers, implantable defibrillators, heart valves, ablation systems, and vascular stents. In FY25, it generated $12.4 billion in revenue (37.2% of total revenue), growing 5.5%. Medtronic continues to lead in innovations like leadless pacing and pulsed field ablation, addressing both chronic and acute cardiac conditions globally.
• Cardiac Rhythm & Heart Failure (CRHF): CRHF focuses on devices tha manage abnormal heart rhythms and heart failure. It includes pacemakers like the Micra leadless system, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors. The segment also includes cardiac ablation systems and remote monitoring services.• Structural Heart & Aortic (SHA): SHA provides solutions for heart valve disorders and aortic diseases. It includes transcatheter aortic valve replacement (TAVR) systems like Evolut FX, surgical heart valves, perfusion systems, and endovascular stent grafts. These devices are used in both minimally invasive and open-heart procedures.• Coronary & Peripheral Vascular (CPV): CPV delivers therapies for coronary artery disease and peripheral vascular conditions. It includes druge luting stents (e.g., Onyx Frontier), angioplasty balloons, renal denervation systems (e.g., Symplicity Spyral), and venous disease treatments like VenaSeal.
Neuroscience: The Neuroscience segment addresses neurological and musculoskeletal disorders through surgical and therapeutic technologies. It includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation. This segment integrates robotics, AI, and navigation systems to improve surgical precision and patient outcomes. In FY25, it generated $9.8 billion in revenue (29.4% of total revenue), growing 4.7%. Medtronic's innovations in spine surgery, stroke treatment, and neuromodulation continue to drive global adoption.
• Cranial & Spinal Technologies (CST): CST develops surgical solutions for spine and cranial procedures. It includes implants, biologics, and enabling technologies like Mazor robotics, StealthStation navigation, and UNiD AI-driven planning. These tools help surgeons perform complex procedures with greater accuracy.• Specialty Therapies: This subsegment includes neurovascular, ENT (ear, nose, and throat), and pelvic health therapies. It offers stroke treatment devices like Solitaire and Pipeline, sinus implants like Propel, and bladder control systems like InterStim. These minimally invasive solutions address critical conditions and improve quality of life.• Neuromodulation: Neuromodulation provides implantable systems for managing chronic pain, movement disorders, and epilepsy. It includes spinal cord stimulators (e.g., Intellis, Inceptiv), deep brain stimulation (e.g., Percept), and drug infusion pumps (e.g., SynchroMed). These technologies personalize therapy using real-time data.Medical Surgical: The Medical Surgical segment supports hospitals and surgical centers with advanced tools and monitoring systems. It includes Surgical & Endoscopy and Acute Care and Acute Care & Monitoring sub-segments. This segment offers robotic-assisted surgery, AI-powered endoscopy, and patient monitoring solutions. In FY25, it generated $8.4 billion in revenue (25.1% of total revenue), a decrease of 0.1%.• Surgical & Endoscopy (SE): SE provides advanced surgical instruments and digital surgery platforms. It includes stapling systems (e.g., Tri-Staple), vessel sealers (e.g., LigaSure), robotic-assisted surgery (Hugo RAS), and AI-powered endoscopy (GI Genius). These tools enhance surgical precision and efficiency.• Acute Care & Monitoring (ACM): ACM focuses on patient monitoring and respiratory care. It includes pulse oximetry (Nellcor), capnography (Microstream), airway management (Shiley), and brain monitoring (BIS). These solutions help clinicians manage critical care and reduce complications.
Diabetes: The Diabetes segment is dedicated to managing Type 1 and Type 2 diabetes through smart, connected technologies. It includes insulin pumps (e.g., MiniMed 780G), continuous glucose monitoring (CGM) systems (e.g., Guardian), and smart insulin pens (e.g., InPen). In FY25, the segment generated $2.8 billion in revenue (8.2% of total revenue), growing 10.7%. Medtronic's diabetes solutions aim to automate insulin delivery and simplify disease management. The MiniMed 780G system features SmartGuard technology, which adjusts insulin every 5 minutes and includes a meal detection algorithm. The Guardian CGM system provides real-time glucose data, while the InPen smart pen integrates with CGM to guide dosing. Medtronic is focused on expanding access to automated insulin delivery systems and competing with pharmaceutical alternatives by emphasizing long-term glycemic control and patient empowerment.
Revenue Trend and Adjusted Operating Profit vs. Margin Trend
4Q25
Total revenue grew by 3.9% YoY to $8.9 billion (+1.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments. International markets and new product launches made significant contributions to the growth. Cardiovascular segment revenue grew 6.6% YoY to $3.3 billion, driven by a 9.2% YoY increase in the Cardiac Rhythm & Heart Failure segment, a 6.9% YoY increase from the Structural Heart & Aortic segment, offset by a 0.2% YoY decline in the Coronary & Peripheral Vascular segment. Neuroscience segment revenue increased 2.9% YoY to $2.6 billion, driven by a 4.0% YoY increase in the Cranial & Spinal Technologies segment, a 9.5% YoY increase in the Neuromodulation segment, offset by a 2.4% YoY decline in the Specialty Therapies segment.
Medical Surgical segment revenue improved 0.6% YoY to $2.2 billion, driven by a 0.2% YoY increase in the Surgical & Endoscopy segment, and a 6.3% YoY increase in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.3% YoY to $728.0 million, driven by strong US adoption of the MiniMed 780G system with high Continuous Glucose Monitor attachment and international pump upgrades to the Simplera Sync sensor.
Adjusted operating income grew 7.6% YoY to $2.5 billion (-0.3% vs. consensus), and the corresponding margin improved ~94 bps to 27.8%, driven by strong revenue growth across key portfolios and disciplined expense management. Operating leverage from higher sales and lower SG&A as a percentage of revenue also contributed to margin expansion. Adjusted net income increased 7.8% YoY to $2.1 billion (+2.7% vs. consensus), and the corresponding margin grew ~84 bps to 23.3%. Adjusted diluted earnings per share came in at $1.62 (4Q24: $1.46), beating the consensus estimates by 2.7%.
4Q25 Revenue
FY25
Total revenue grew by 3.6% to $33.5 billion (+0.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments, with notable growth in Cardiac Ablation. Continued innovation, international expansion, and new product approvals also supported overall growth. Cardiovascular segment revenue grew 5.5% to $12.5 billion, driven by a 6.6% increase in the Cardiac Rhythm & Heart Failure segment, a 2.3% increase from the Coronary & Peripheral Vascular segment, offset by a 0.1% decline in the Structural Heart & Aortic segment. Neuroscience segment revenue increased 4.7% to $9.9 billion, driven by a 4.6% increase in the Cranial & Spinal Technologies segment, a 10.7% increase in the Specialty Therapies segment, and a 1.2% growth in the Neuromodulation segment.
Medical Surgical segment revenue declined 01% to $8.4 billion, due to 0.2% decline in the Surgical & Endoscopy segment, and offset by 0.1% growth in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.7% to $2.7 billion. Adjusted operating income grew 4.5% to $8.6 billion (in line with consensus), and the corresponding margin improved ~23 bps to 25.8%, driven by strong revenue growth and lower SG&A expenses. Adjusted net income increased 2.3% to $7.1 billion (+0.8% vs. consensus), while the corresponding margin contracted ~27 bps to 21.1%. Adjusted diluted earnings per share came in at $5.49 (FY24: $5.20), beating the consensus estimates by 0.6%.
FY25 Revenue
Company DescriptionMedtronic plc (Parent)
Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, committed to alleviating pain, restoring health, and extending life. With over 95,000 employees across more than 150 countries, Medtronic delivers innovative solutions for more than 70 health conditions. The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. These segments encompass a wide range of technologies, including cardiac rhythm devices, spinal and brain therapies, surgical tools, and insulin delivery systems.
New Diabetes Company (Spin-Off)
The New Diabetes Company will emerge as a leading global direct-to-consumer diabetes care provider, uniquely offering a comprehensive ecosystem for intensive insulin management. With a portfolio that includes insulin pumps, continuous glucose monitoring (CGM) systems, and digital health solutions, it empowers individuals to manage diabetes with greater ease and freedom. Backed by a dedicated team of over 8,000 employees and a robust global infrastructure, the company is poised to accelerate innovation in Automated Insulin Delivery and Smart Multiple Daily Injections (MDI).
Organization Structure
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Comtech Rejoins iCERT, Deepening Commitment to Public Safety Innovation
Renewed Membership Reinforces Public Safety Commitment and Expands Advocacy Platform CHANDLER, Ariz., June 20, 2025--(BUSINESS WIRE)--Jun. 20, 2025-- Comtech Telecommunications Corp. (NASDAQ: CMTL) ("Comtech" or the "Company"), a global communications technology leader, today announced that its Terrestrial & Wireless Networks ("T&W") business segment has rejoined the Industry Council for Emergency Response Technologies, Inc. ("iCERT"). Founded in 2005, iCERT is a commercial sector trade association that brings together leading technology companies to drive innovation, shape effective policy, and promote open standards that improve public safety and emergency response. This return to iCERT is part of a series of strategic moves by the T&W business segment, including the launch of Allerium Mira - a cloud-native call handling platform designed to simplify complexity and support evolving 9-1-1 needs. Together, these efforts reflect a renewed commitment to public safety and essential service providers, backed by the same trusted team, proven solutions, and industry-wide support. "We're excited to collaborate with iCERT as it expands its focus on key issues and innovations in emergency communications," said Susan Ornstein, Senior Director of Legal & Regulatory Affairs of Comtech T&W, who joined the association's board of directors earlier this month. "Under its new leadership, iCERT is amplifying the voice of its members on public policy issues and engaging partner associations like NASNA, NENA, and APCO to advance shared priorities across the public safety community. Together with iCERT, Comtech is well positioned to address pressing public safety and regulatory matters, and advocate for federal funding, legislation, and FCC policy updates." "Few organizations have meant as much to me throughout my career as iCERT," said Jeff Robertson, President of Comtech T&W. "Twenty years ago, I worked alongside two industry visionaries to establish this organization with the shared goal of fostering collaboration between the public and private sectors. I was privileged to serve as iCERT's inaugural executive director and have remained a strong advocate of its mission throughout my career. Seeing our company rejoin the iCERT community is especially meaningful. Comtech is committed to delivering results that help communities become safer, more connected, and resilient, and iCERT is a vital partner in advancing that work." "iCERT stands committed to propelling public safety forward, facilitating collaboration among its member base and industry stakeholders, and creating an environment that fosters innovation and progress," said Don Brittingham, Interim Executive Director of iCERT. "Members like Comtech play a vital role in strengthening the organization's depth and breadth of experience across the full public safety call flow. I am excited to welcome Jeff Robertson and his team back to iCERT and look forward to empowering public safety together." About Comtech Comtech Telecommunications Corp. is a leading provider of satellite and space communications technologies; terrestrial and wireless network solutions; Next Generation 9-1-1 (NG9-1-1) and emergency services; and cloud native capabilities to commercial and government customers around the world. Through its culture of innovation and employee empowerment, Comtech leverages its global presence and decades of technology leadership and experience to create some of the world's most innovative solutions for mission-critical communications. For more information, please visit About iCERT iCERT—The Industry Council for Emergency Response Technologies—is the only industry trade association focused exclusively on emergency response technologies and related equipment, systems, and services. iCERT is dedicated to improving public safety through innovation. For more information, please visit Forward-Looking Statements Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company's Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings. View source version on Contacts Investor Relations Maria Ceriello631-962-7102investors@ Media Contact Jamie
Bloomberg
33 minutes ago
- Bloomberg
Rebecca Shi on ICE Raids Scaring Essential US Workers
Rebecca Shi, American Business Immigration Coalition Executive Director, discusses the impact ICE raids are having on the US labor force and shares her thoughts on whether or not the deportations themselves or the fear the deportations are instilling on workers are putting more stress on the job market. She speaks with Joe Mathieu and Tyler Kendall on the late edition of Bloomberg's "Balance of Power." (Source: Bloomberg)
Yahoo
33 minutes ago
- Yahoo
Trade Idea Moves Twins' Byron Buxton to Phillies
Trade Idea Moves Twins' Byron Buxton to Phillies originally appeared on Athlon Sports. The Boston Red Sox may have started a new trend in their trade of Rafael Devers: using the trade market to offload a superstar previously signed to lengthy, big-money deals. Advertisement In 2023, Devers signed a 10-year, $313.5 million extension to his already-existing contract, which was set to expire at the end of the season. The financial commitments the Red Sox had to the slugger did not deter them from moving him just one and a half years into the deal, as they traded him to the San Francisco Giants. Such a transaction has only happened one other time in MLB history – when the Miami Marlins traded Giancarlo Stanton to the New York Yankees three years into a 13-year, $325 million deal in 2018. That beckons a double-barreled question: When will this kind of deal happen again, and who will it involve? According to Bleacher Report's Zachary D. Rymer, the Minnesota Twins and Philadelphia Phillies should field calls to each other about All-Star outfielder Byron Buxton, a player who also won a Gold Glove Award in 2017. Buxton is currently in year four of a seven-year, $100 million deal with the Twins. Jul 31, 2024; New York City, New York, USA; Minnesota Twins center fielder Byron Buxton (25) celebrates his solo home run against the New York Mets with teammates in the dugout during the second inning at Citi Field. Mandatory Credit: Brad Penner-USA TODAY Sports © Brad Penner-USA TODAY Sports "Buxton's long-term future... remains suspect. He is keeping up his act as a two-way star when he does play, but he's a 31-year-old with one of the most cluttered injury histories in recent memory. And as such, the Twins should be wondering if this is their last best chance to sell high on him," Rymer wrote. Advertisement "Because he has full no-trade protection, he'll only go anywhere if he wants to. But if the Twins present him with a chance to spend the rest of his prime with a proper World Series contender, it could be hard for him to turn it down." Rymer sees the Phillies as an ideal trade destination for Buxton because he would fulfill a need the team has been missing for years. "Not since the early days of Odúbel Herrera's career have the Phillies had a reliable regular in center field, much less a star. They have managed to succeed despite this, but that should raise questions about how far they could go if they actually went out and got a star to roam the middle of their outfield," Rymer wrote. "A trade for Buxton would fit the bill, and such a deal would be right up Dave Dombrowski's alley." Advertisement Through 57 games this season, Buxton is hitting .280 with 15 home runs, 45 RBIs, 12 stolen bases, a .898 OPS, and 2.6 WAR (according to Baseball Reference). Related: Phillies' Cristopher Sánchez Reflects on Best Start of 2025 This story was originally reported by Athlon Sports on Jun 20, 2025, where it first appeared.
